What one share of Sinovac Biotech holds
We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs.
Sinovac Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $5.37 |
|---|---|
| Profit | −$0.83 |
| Capex (buildings and equipment) | $0.68 |
| Free cash flow | −$7.81 |
| Dividends | $49.18 |
| Cash and investments | $6.79 |
| Debt | $6.89 |
| Book value | $61.77 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $1.96 | $0.46 | $0.10 | $1.03 | — | $1.98 |
| 2010 | $0.63 | −$0.16 | $0.47 | −$0.74 | — | $2.33 |
| 2011 | $1.04 | −$0.02 | $0.28 | −$0.03 | — | $2.37 |
| 2012 | $0.90 | −$0.27 | $0.29 | −$0.59 | — | $2.14 |
| 2013 | $1.29 | $0.13 | $0.09 | $0.01 | — | $2.32 |
| 2014 | $1.12 | −$0.03 | $0.19 | −$0.37 | — | $2.27 |
| 2015 | $1.20 | −$0.03 | $0.09 | −$0.02 | — | $2.14 |
| 2016 | $1.27 | −$0.01 | $0.22 | −$0.47 | — | $2.03 |
| 2017 | $3.05 | $0.45 | $0.21 | $0.84 | — | $2.64 |
| 2018 | $3.53 | $0.34 | $0.09 | $0.04 | — | $3.56 |
| 2019 | $2.24 | $0.41 | $0.10 | $0.26 | — | $2.97 |
| 2020 | $4.49 | $0.97 | $1.12 | $3.10 | — | $7.52 |
| 2021 | $270.47 | $113.44 | $8.30 | $205.70 | — | $125.41 |
| 2022 | $20.53 | $0.20 | $4.37 | −$15.49 | — | $118.38 |
| 2023 | $6.54 | −$0.19 | $2.17 | −$0.24 | — | $115.72 |
| 2024 | $5.03 | $1.26 | $1.34 | −$2.13 | — | $114.98 |
| 2025 | $5.37 | −$0.83 | $0.68 | −$7.81 | — | $61.77 |
Common questions about Sinovac Biotech
How much does one share of Sinovac Biotech earn?
Over its latest fiscal year, Sinovac Biotech lost $0.83 for each share on $5.37 of sales.
Does Sinovac Biotech pay a dividend?
Yes. Sinovac Biotech paid $49.18 per share in dividends over its latest fiscal year.
What is Sinovac Biotech’s book value per share?
Sinovac Biotech’s book value is $61.77 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Sinovac Biotech have?
Each share of Sinovac Biotech has $6.79 of cash and investments and $6.89 of debt, as of December 31, 2025.
What is Sinovac Biotech’s free cash flow per share?
−$7.81 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Sinovac Biotech bought back shares?
Sinovac Biotech’s share count rose about 67% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.